These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 15637086)

  • 1. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.
    De Bruin ML; Pettersson M; Meyboom RH; Hoes AW; Leufkens HG
    Eur Heart J; 2005 Mar; 26(6):590-7. PubMed ID: 15637086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
    Thomas D; Karle CA; Kiehn J
    Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
    Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
    Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of HERG potassium channel function by drug action.
    Thomas D; Karle CA; Kiehn J
    Ann Med; 2004; 36 Suppl 1():41-6. PubMed ID: 15176423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
    Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
    J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hERG potassium channel as a therapeutic target.
    Witchel HJ
    Expert Opin Ther Targets; 2007 Mar; 11(3):321-36. PubMed ID: 17298291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HERG block, QT liability and sudden cardiac death.
    Brown AM
    Novartis Found Symp; 2005; 266():118-31; discussion 131-5, 155-8. PubMed ID: 16050265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-cardiovascular drugs that inhibit hERG-encoded potassium channels and risk of sudden cardiac death.
    van Noord C; Sturkenboom MC; Straus SM; Witteman JC; Stricker BH
    Heart; 2011 Feb; 97(3):215-20. PubMed ID: 20406763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
    Finlayson K; Witchel HJ; McCulloch J; Sharkey J
    Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioids-induced inhibition of HERG ion channels and sudden cardiac death, a systematic review of current literature.
    El Sherbini A; Liblik K; Lee J; Baranchuk A; Zhang S; El-Diasty M
    Trends Cardiovasc Med; 2024 Jul; 34(5):279-285. PubMed ID: 37015297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. hERG: protein trafficking and potential for therapy and drug side effects.
    Staudacher I; Schweizer PA; Katus HA; Thomas D
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):23-30. PubMed ID: 20047143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
    Shah RR
    Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
    Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
    Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facilitation of hERG Activation by Its Blocker: A Mechanism to Reduce Drug-Induced Proarrhythmic Risk.
    Furutani K
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular determinants of high-affinity drug binding to HERG channels.
    Mitcheson JS; Perry MD
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):667-74. PubMed ID: 14579516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antipsychotic drug chlorpromazine inhibits HERG potassium channels.
    Thomas D; Wu K; Kathöfer S; Katus HA; Schoels W; Kiehn J; Karle CA
    Br J Pharmacol; 2003 Jun; 139(3):567-74. PubMed ID: 12788816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QT interval prolongation and cardiac risk assessment for novel drugs.
    Picard S; Lacroix P
    Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lead compound optimization strategy(5) – reducing the hERG cardiac toxicity in drug development].
    Zhou SB; Wang J; Liu H
    Yao Xue Xue Bao; 2016 Oct; 51(10):1530-9. PubMed ID: 29932317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Support vector machines classification of hERG liabilities based on atom types.
    Jia L; Sun H
    Bioorg Med Chem; 2008 Jun; 16(11):6252-60. PubMed ID: 18448342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inherited long QT syndrome: from ion channel to bedside.
    Vincent GM; Timothy K; Fox J; Zhang L
    Cardiol Rev; 1999; 7(1):44-55. PubMed ID: 10348966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.